Amphista Therapeutics, a provider of next-generation targeted protein degradation solutions, has secured $53 million in Series B financing. Forbion and Gilde Healthcare led the round.
Source: Press Release
Amphista Therapeutics nabs $53m Series B
Amphista Therapeutics, a provider of next-generation targeted protein degradation solutions, has secured $53 million in Series B financing.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: